kringle-pharmaCo., Ltd.

NEWS

notice

Jun 16, 2014 Notice

Kringle Initiates Phase I/II Clinical Trial of Recombinant Human HGF for the Treatment of Acute Spinal Cord Injury.

Kringle Initiates Phase I/II Clinical Trial of Recombinant Human HGF for the Treatment of Acute Spinal Cord Injury.